SAFETY DATA SHEET



1. Identification

Product identifier ARRANON INJECTION

Other means of identification

Synonyms ARRANON INJECTION 5 MG/ML * ATRIANCE INFUSION * 506u78 INJECTION * GI262250X

INJECTION * NDC 0007-4401-01 * NDC 0007-4401-06 * NELARABINE, FORMULATED

PRODUCT

Recommended use Medicinal Product.

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Recommended restrictions No other uses are advised.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

GlaxoSmithKline US 5 Moore Drive

Research Triangle Park, NC 27709 USA

US General Information (normal business hours): +1-888-825-5249

Email Address: msds@gsk.com Website: www.gsk.com EMERGENCY PHONE NUMBERS -TRANSPORT EMERGENCIES::

US / International toll call +1 703 527 3887

available 24 hrs/7 days; multi-language response

2. Hazard(s) identification

Classified hazards

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Label elements

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Hazard(s) not otherwise classified (HNOC)

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
506U78	NELZARABINE * 2-AMINO-9-BETA-D-ARABINOFURANOSYL -6-METHOXY-9H-PURINE * 2-AMINO-6-METHOXYPURINE ARABINOSIDE * GI262250X * 506U78 * BW 506U78 * 1540 (GW ACN)	121032-29-9	0.5
Other components below reportable levels			99.5

^{*}Designates that a specific chemical identity and/or percentage of composition has been withheld as a trade secret.

4. First-aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if

symptoms develop or persist. Under normal conditions of intended use, this material is not

expected to be an inhalation hazard.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

Material name: ARRANON INJECTION SDS US

Eve contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion

If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control center immediately. Do not induce vomiting without

advice from poison control center.

Most important

symptoms/effects, acute and

delayed

None known. The following adverse effects have been noted with the rapeutic use of this material: temporary decrease in white blood cell counts; abnormal nervous system sensations; gastrointestinal distress

. Prolonged exposure may cause chronic effects.

Indication of immediate medical attention and special treatment needed

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control

information center.

General information

In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media Unsuitable extinguishing

Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

No unusual fire or explosion hazards noted.

None known.

media

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting equipment/instructions

Move containers from fire area if you can do so without risk.

Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up Large Spills: Stop the flow of material, if this is without risk. Dike the spilled material, where this is possible. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS.

Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Avoid prolonged exposure. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities

Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

Occupational exposure limits

G	S	K

Components	Туре	Value	Note
NELARABINE (CAS 121032-29-9)	8 HR TWA	10 mcg/m3	
,	OHC	4	REPRODUCTIVE HAZARD, CARCINOGEN

Biological limit values

No biological exposure limits noted for the ingredient(s).

Exposure guidelines Appropriate engineering

General ventilation normally adequate.

controls

Material name: ARRANON INJECTION 128182 Version #: 06 Revision date: 11-20-2014 Issue date: 11-20-2014

Individual protection measures, such as personal protective equipment

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection For prolonged or repeated skin contact use suitable protective gloves.

Other Wear suitable protective clothing as protection against splashing or contamination.

Respiratory protection
No personal respiratory protective equipment normally required. Use a NIOSH/MSHA approved

respirator if there is a risk of exposure to dust/fume at levels exceeding the exposure limits.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. New or expectant mothers might be at greater risk from overexposure. Risk assessments must take this into consideration. Female employees anticipating pregnancy or with a confirmed pregnancy must be encouraged to notify an occupational health professional or their line manager. This will act as the trigger for individual re-assessment of the employee's work practices.

9. Physical and chemical properties

Appearance

Physical state Liquid. Form Vial.

Color Not available.
Odor Not available.
Odor threshold Not available.
pH Not available.
Melting point/freezing point Not available.
Initial boiling point and boiling Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

(0/ \

Not available.

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Vapor pressure Not available.

Vapor density Not available.

Relative density Not available.

Solubility(ies)

Solubility (water) Not available.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

Other information

Percent volatile 99 % estimated

10. Stability and reactivity

ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

128182 Version #: 06 Revision date: 11-20-2014 Issue date: 11-20-2014

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid

Contact with incompatible materials.

Incompatible materials

Strong oxidizing agents.

Hazardous decomposition

products

Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

11. Toxicological information

Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Health injuries are not known or expected under normal use. Skin contact

Eye contact Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation.

Health injuries are not known or expected under normal use. May be harmful if swallowed. Ingestion

However, ingestion is not likely to be a primary route of occupational exposure.

Symptoms related to the physical, chemical and

toxicological characteristics

None known.

The following adverse effects have been noted with therapeutic use of this material: temporary decrease in white blood cell counts; abnormal nervous system sensations; gastrointestinal

distress.

Prolonged exposure may cause chronic effects.

Information on toxicological effects

Acute toxicity Health injuries are not known or expected under normal use. May be harmful if swallowed.

Components Species **Test Results**

506U78 (CAS 121032-29-9)

Chronic Oral

LOEL Monkey 10 mg/kg/day Intravenous route

Health injuries are not known or expected under normal use. Skin corrosion/irritation

Serious eye damage/eye

Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation.

irritation

506U78 Acute ocular irritation, Application of 0.1 mL (61 mg, as a

solid) resulted in maximum average score of 6.7 (Draize

grade 1)

Result: Minimal Irritant Species: Rabbit

Respiratory or skin sensitization

Respiratory sensitization Not available.

Skin sensitization Health injuries are not known or expected under normal use.

Sensitization

506U78 Maximisation assay (Magnusson and Kligman)

Result: Negative Species: Guinea pig

Health injuries are not known or expected under normal use. Contains a component that produced Germ cell mutagenicity

mutagenicity in laboratory tests.

Mutagenicity

506U78 Mouse Lymphoma Cell (L5178Y) Mutation Assay, GLP assay

Result: Positive

SAR / QSAR, DEREK, Lhasa, UK Result: Plausible (chromosome damage)

Carcinogenicity Health injuries are not known or expected under normal use. Contains a component listed as a

carcinogen by: (GSK).

506U78 SAR / QSAR Result: Plausible

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

^{*} Estimates for product may be based on additional component data not shown.

Reproductive toxicity

Health injuries are not known or expected under normal use. Contains components which have been classified as: Suspected of damaging fertility or the unborn child.

Reproductivity

506U78

Embryo-foetal development - Intravenous

Result: Foetal NOAEL not identified; decreased foetal weight with doses = 300 mg/kg/day (intravenous infusion); delayed foetal skeletal ossification and increased malformations with doses >/= 30 mg/kg/day (lowest dose); maternal NOAEL =

100 mg/kg/day Species: Rabbit

Specific target organ toxicity single exposure

None known.

506U78

May cause damage to organs through prolonged or repeated exposure.

Specific target organ toxicity repeated exposure

Repeat dose non-clinical studies; clinical observation Organ: bone marrow; blood; central nervous system;

gastrointestinal tract

Aspiration hazard Not available.

Chronic effects Prolonged exposure may cause chronic effects.

Further information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause

adverse effects.

12. Ecological information

Ecotoxicity Not expected to be harmful to aquatic organisms.

Components		Species	Test Results
506U78 (CAS 121032-29	9-9)		
Aquatic			
Acute			
Activated Sludge Respiration	IC50	Residential sludge	> 1000 mg/l, 3 hours
Algae	EC50	Green algae (Selenastrum capricornutum)	> 100 mg/l, 96 hours Static test, OECD 201
	NOEC	Green algae (Selenastrum capricornutum)	> 100 mg/l, 96 hours
Crustacea	EC50	Water flea (Daphnia magna)	> 1070 mg/l, 48 hours OECD 202
	NOEC	Water flea (Daphnia magna)	260 mg/l, 48 hours
Fish	EC50	Rainbow trout (Adult Oncorhyncus mykiss)	> 100 mg/l, 96 hours Static , OECD 203
	NOEC	Rainbow trout (Adult Oncorhyncus mykiss)	> 100 mg/l, 96 hours

^{*} Estimates for product may be based on additional component data not shown.

Persistence and degradability

Photolysis

UV/visible spectrum wavelength

506U78 294 nm

Hydrolysis

Half-life (Hydrolysis-neutral)

506U78 > 1 Years Measured

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

40 %, 28 days Modified Zahn-Wellens, Activated sludge

Percent degradation (Aerobic biodegradation-soil)

506U78 48 - 67.9 %, 64 days

Bioaccumulative potential

Partition coefficient n-octanol / water (log Kow)

506U78 < 1

Material name: ARRANON INJECTION 128182 Version #: 06 Revision date: 11-20-2014 Issue date: 11-20-2014 Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

506U78 1.73 - 1.94 Measured, pH 5.5-7.8

Mobility in general

Volatility

Henry's law

506U78 0 atm m^3/mol Estimated

Other adverse effects Not available.

13. Disposal considerations

Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not **Disposal instructions**

discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable

regulations.

Local disposal regulations Dispose in accordance with all applicable regulations.

The waste code should be assigned in discussion between the user, the producer and the waste Hazardous waste code

disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions). Avoid discharge into water courses or onto the ground.

Empty containers should be taken to an approved waste handling site for recycling or disposal. Contaminated packaging

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

DOT

Not regulated as a dangerous good.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

environment. These materials may not be transported in bulk.

the IBC Code

15. Regulatory information

US federal regulations

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - Yes

Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous No

chemical

SARA 313 (TRI reporting)

Not regulated.

Material name: ARRANON INJECTION 6/8

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

US state regulations

US. California Controlled Substances. CA Department of Justice (California Health and Safety Code Section 11100)

Not listed

US. Massachusetts RTK - Substance List

Not regulated.

US. New Jersey Worker and Community Right-to-Know Act

Not listed.

US. Pennsylvania Worker and Community Right-to-Know Law

Not listed.

US. Rhode Island RTK

Not regulated.

US. California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or region

oountry(3) or region	inventory name	On inventory (yes/no)
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

Toxic Substances Control Act (TSCA) Inventory

16. Other information, including date of preparation or last revision

Inventory name

 Issue date
 11-20-2014

 Revision date
 11-20-2014

Version # 06

United States & Puerto Rico

Further information HMIS® is a registered trade and service mark of the NPCA.

HMIS® ratings Health: 1*

Flammability: 0 Physical hazard: 0

NFPA ratings Health: 1

Flammability: 0
Instability: 0

References GSK Hazard Determination

Disclaimer The information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

the culturality of the material of production any particular purpose.

Material name: ARRANON INJECTION

128182 Version #: 06 Revision date: 11-20-2014 Issue date: 11-20-2014

No

On inventory (yes/no)*

Revision Information

Product and Company Identification: Business Units Composition / Information on Ingredients: Ingredients Physical & Chemical Properties: Transport Information: Agency Name, Packaging Type, and Transport Mode Selection Regulatory Information: United States GHS: Classification

Material name: ARRANON INJECTION